TRADU
Tradu, the powerful multi-asset trading platform, has launched a new crypto exchange with low, transparent fees tailored for active traders and investors seeking a trustworthy and secure platform for their crypto assets. From today, crypto traders can securely invest in over 40 coins including Bitcoin and Ethereum via Tradu’s multi-asset trading platform. Tradu is part of Stratos Group International, LLC (“Stratos”), a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF).
Tradu is taking a fresh approach to crypto, offering a simple and transparent cost structure that saves investors up to 95% of the fees that can be charged in crypto trading. The platform displays commissions and real-time spreads before orders are placed, giving traders full transparency on all transaction costs. Tradu charges just 0.1% commission with instant rebates of 0.02% and 0.05% for larger trade sizes. The commission for a 1 BTC trade (at a price of $60,000) is just $30 at Tradu versus as much as $600 at other exchanges.*
Tradu clients can also choose to trade on a commission-free profile opting to instead add the fee to the spread. Clients can simply click to change between the Zero Commission and the Raw Spreads profile options in the platform. Clients have the flexibility to choose the profile that best suits their trading style.
Other key features include:
Uniform trading fees: Tradu maintains equal fees for maker and taker transactions, promoting fairness, simplicity and transparency in trading.
Free crypto deposits and easy withdrawals: Crypto deposits are free with Tradu while withdrawals are easy and fees are simple and clear.
Comprehensive support: Access customer support through various channels, including email, chat, and phone, ensuring prompt assistance for user queries.
Brendan Callan, CEO of Tradu, commented: “At Tradu, we are real supporters of crypto. It’s a huge market with significant investor interest and as a true multi-asset trading platform, it’s important for us to offer our clients access to both traditional assets and new digital assets. We are bringing institutional-grade pricing and infrastructure to the retail crypto market, providing traders with upfront costs and tight, transparent spreads enabling active traders and investors to maximise their returns. Tradu is focused on creating stable, secure and frictionless cryptocurrency trading through technology, delivering a better, safer and lower cost service. Clients can reach out to our support team for detailed instructions on how to transfer their crypto portfolio over to Tradu.”
In addition to cryptocurrencies, Tradu users can also access over 10,000 trading products across equities, forex and CFDs on commodities, stocks, treasuries and indices all from one powerful portal that can be accessed via a user-friendly mobile app and web platforms.
Visit crypto.tradu.com to sign up and gain access to a wide range of assets**.
Notes to editors
* Costs calculated based on buying one Bitcoin at a price of $60,000. Tradu cost includes a 0.05% rebate based on order size. Comparative pricing based on a standard account type and information from broker websites as of 1st May 2024. It does not reflect the whole market. Actual fees may vary due to factors like account type, rebates, volume, and market conditions.
**Products vary depending on location, visit tradu.com to check which products are available in your region.
About Tradu
Tradu is headquartered in London with offices around the world. The global Tradu team speaks more than two dozen languages and prides itself on its responsive and helpful client support.
Stratos also operates FXCM, an FX and CFD platform founded in 2001. Stratos will continue to offer FXCM services alongside Tradu’s multi-asset platform.
Stratos subsidiaries are authorised and regulated in the UK, Europe, Australia and South Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508810010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom